Browsing Tag
THRIVE-2
1 post
Viridian Therapeutics reports 70% durability at one year in Phase 3 THRIVE trial for veligrotug in thyroid eye disease
Viridian's veligrotug maintained a 70% response at 52 weeks in TED patients; BLA filing expected in H2 2025. Find out how this breakthrough could reshape care.